$0.700
-0.088 (-12.50%)收盤時
VRAX 資訊
VRAX 事件
Virax Biolabs Signs Distribution Agreements for Immune Products
Virax Biolabs announced that, through its China subsidiary, Shanghai Xitu Consulting Co., Ltd., it has entered into non-exclusive distribution agreements with AmyJet Scientific Inc., Jiangsu Real-Gen Biotechnology Co., Ltd., and Zhixi (Shanghai) Biotechnology Co., Ltd. for its ImmuneSelect research-use immune profiling products. ImmuneSelect is Virax's commercially available research-use-only immune profiling portfolio and is distinct from ViraxImmune, the company's in-development diagnostic platform. The appointments build on initial ImmuneSelect product sales from Virax's existing mainland China operations and complement its previously announced exclusive commercial supply agreement with Fosun Diagnostics across six Southeast Asian markets. Under the agreements, the distributors will purchase ImmuneSelect products from Virax for resale within their respective authorised markets and customer segments. The distributors will manage local sales, customer engagement and customer training on product use and storage, with Virax providing product supply, documentation and technical support.
Virax Biolabs Files to Sell 1.68M Ordinary Shares
Virax Biolabs files to sell 1.68M ordinary shares for holders
Virax Biolabs Signs Exclusive Supply Agreement with Fosun Diagnostics
Virax Biolabs Group announced that its wholly owned subsidiary, Virax Biolabs Limited, has entered into an exclusive multi-country commercial supply agreement with Fosun Diagnostics for the Company's ImmuneSelect research-use immune profiling product line. The agreement covers six Southeast Asian markets, including Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia, and establishes a framework for immediate product supply under purchase orders, supporting near-term potential revenue opportunities and regional commercial expansion.
Virax Biolabs Group Ltd Trading Halted, News Pending
Virax Biolabs Group Ltd trading halted, news pending
Virax Biolabs Shareholders Approve 1-for-25 Share Consolidation
Virax Biolabs Group announced that the board of directors of the Company approved a share consolidation of the Company's authorized, issued and outstanding ordinary shares of $0.001 par value each at a ratio of 1-for-25 effective 26 June. The shareholders approved the Share Consolidation at the adjourned extraordinary general meeting of the shareholders held on Friday, June 12. At the opening of trading on June 26 the Company's ordinary shares will begin trading on a post-Share Consolidation basis on the Nasdaq Capital Market under the same symbol "VRAX", but under a new CUSIP number of G9495L133. The objective of the Share Consolidation is to enable the Company to regain compliance with Nasdaq Marketplace Rule 5550 and maintain its listing on the Nasdaq Capital Market. Upon the effectiveness of the Share Consolidation, every twenty-five issued and outstanding ordinary shares of a par value of $0.001 each will automatically be consolidated into one issued and outstanding ordinary share of a par value of $0.025 each.
相關文章
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。